Two Radiofrequency Ablation Settings Compared for Treating Atrial Fibrillation
Compares high-power short ablation with standard low-power ablation in adults with atrial fibrillation.
Plain-language title generated from the registry record
Registry title: Comparative Evaluation of the Efficacy and Safety of High-Power Short-Duration Radiofrequency Ablation and Standard Low-Power Ablation in Catheter Treatment of Atrial Fibrillation
Key facts
- Where
- Moscow, RussiaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07728539, who can take part
Where in Russia
- Bakulev National Medical Research Center for Cardiovascular SurgeryMoscow, RussiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bakulev Scientific Center of Cardiovascular Surgery
- Trial code
- NCT07728539
- Record updated
- 27 July 2026
- Original description
Atrial fibrillation (AF) is the most common cardiac arrhythmia and represents one of the leading causes of cardiovascular morbidity and mortality. According to current data, AF is associated with approximately 20% of all ischemic strokes, while the risk of stroke in patients with this arrhythmia is increased fivefold. Ischemic stroke in patients with AF is characterized by a more severe clinical course, more frequently results in death, is associated with significant disability, and carries a higher risk of recurrence compared with strokes of other etiologies. Consequently, the risk of death in patients with AF-associated stroke is doubled, while the economic costs of treatment increase by an average of 1.5 times.Read full original descriptionShow less
Comparative Evaluation of the Efficacy and Safety of High-Power Short-Duration Radiofrequency Ablation and Standard Low-Power Ablation in Catheter Treatment of Atrial Fibrillation
Atrial fibrillation (AF) is the most common cardiac arrhythmia and represents one of the leading causes of cardiovascular morbidity and mortality. According to current data, AF is associated with approximately 20% of all ischemic strokes, while the risk of stroke in patients with this arrhythmia is increased fivefold. Ischemic stroke in patients with AF is characterized by a more severe clinical course, more frequently results in death, is associated with significant disability, and carries a higher risk of recurrence compared with strokes of other etiologies. Consequently, the risk of death in patients with AF-associated stroke is doubled, while the economic costs of treatment increase by an average of 1.5 times.
The aim of the present study is to perform a comparative evaluation of the efficacy of two interventional treatment strategies for atrial fibrillation: very high-power short-duration radiofrequency ablation (90 W) and conventional low-power radiofrequency ablation (35-45 W) for pulmonary vein isolation using the "CLOSE protocol" approach with a non-fluoroscopic navigation system. The efficacy of the interventions will be assessed both in the early postoperative period and during long-term follow-up over 12 months.
Inclusion: Age over 18 years old; Atrial fibrillation resistant to antiarrhythmic therapy; Paroxysmal form of atrial fibrillation; Persistent form of atrial fibrillation; The patient's consent to participate in the study.
Exclusion: Previous "open" cardiac surgery; The presence of another cardiac pathology requiring surgical treatment; Congenital heart defects; Bone marrow diseases; Drug-resistant hypertension (despite hypotensive therapy); The left ventricular ejection fraction is less than 40%; Moderate to severe renal insufficiency (creatinine clearance <50 ml/min); Age under 18 and over 80 years old; Pathology of the blood coagulation system; Organically altered mitral valve; There are reasons to assume that the patient will not show up for subsequent visits (control points of the study) for various reasons; The patient's participation in another clinical trial.